INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

68.14

-0.29 (-0.42%)

At close: 4:00PM EDT

65.97 -2.17 (-3.18%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser

Previous Close	68.43
Open	68.83
Bid	64.62 x 400
Ask	65.97 x 100
Day's Range	67.70 - 69.91
52 Week Range	61.30 - 140.11
Volume	2,082,288
Avg. Volume	2,280,812

Market Cap	14.432B
Beta	1.12
PE Ratio (TTM)	N/A
EPS (TTM)	-1.53
Earnings Date	May 1, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	91.47

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire4 hours ago
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
Reuters5 hours ago
FDA panel against higher dose of Lilly-Incyte arthritis drug
An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
PR Newswire4 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)
NEW YORK , April 20, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Incyte Corporation ("Incyte" ...
Motley Fool4 days ago
3 Biotech Stocks With Major Catalysts Incoming
Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
PR Newswire4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY
NEW YORK , April 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors ...
Bloomberg4 days ago
Eli Lilly's Blockbuster Resurrection Story Has Holes
Its arthritis drug's new lease on FDA life apparently comes with conditions.
MarketWatch4 days ago
Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
MarketWatch5 days ago
Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug
Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.
Reuters5 days ago
FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug
The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...
Motley Fool7 days ago
What Incyte's Phase 3 Fail Means for Immuno-Oncology
Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.
Investor's Business Daily7 days ago
NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
Motley Fool7 days ago
What's Next for Incyte?
With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.
MarketWatch8 days ago
NewLink shares fall on late-stage trial changes
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
Zacks8 days ago
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Motley Fool10 days ago
What Happened With Incyte's IDO Inhibitor Flop
Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.
Zacks11 days ago
Pharma M&A Active This Week: 4 Potential Buyout Targets
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Market Realist11 days ago
Incyte: S&P 500’s Top Gainer on April 12
The S&P 500’s top gainers on April 12 were: Incyte (INCY) gained 5.3%. Micron Technology (MU) gained 4.2%. Host Marriott Financial Trust (HST) gained 4.1%. Deere & Company (DE) gained 4.1%. Discovery (DISCK) gained 3.9%. Incyte
Business Wire11 days ago
Incyte to Report First Quarter Financial Results
Incyte Corporation announced today that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018.
Motley Fool11 days ago
Why One Drug Flop Tanked Incyte's Stock
Biotech is risky business, and Incyte shareholders have not had a good week after a key drug flopped its phase 3.
Barrons.com11 days ago
The Biggest Movers: Incyte Excites; L Brands Slides
Incyte (INCY) popped to the top of among S&P 500 stock performers, helped by an analyst upgrade. Incyte added $3.54, or 5.3%, to $69.83. The S&P 500 gained 21.80 points, or 0.83%, to 2663.99. UBS's Carter ...
Motley Fool11 days ago
Why GoPro, Incyte, and Wynn Resorts Jumped Today
Find out which of these companies jumped on takeover chatter.
Investopedia11 days ago
3 Biotech Stocks Analysts Have Been Too Bullish On
Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.
Market Realist12 days ago
Incyte Advances R&D Strategy with Multiple Partnerships
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.
Market Realist12 days ago
Why Did Bristol-Myers Squibb Stock Fall More Than 3% on April 6?
On April 6, 2018, Incyte (INCY) stock fell nearly 20%, triggered by news of the failure of the clinical trial for its skin cancer drug. The trial is for the assessment of the combo-therapy approach of Incyte’s epacadostat and Merck’s (MRK) Keytruda for the treatment of skin cancer. The Phase 3 trial results were unexpectedly found to yield unsuccessful results since it did not achieve the main goal of the study.
Market Realist12 days ago
Olumiant Could Boost Incyte’s Revenues
In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis (or RA) and who did not respond sufficiently or could not tolerate disease-modifying antirheumatic drugs (or DMARDs). In July 2017, the drug was approved by the Japan Ministry of Health, Labor, and Welfare for RA patients who don’t respond sufficiently to standard-of-care treatment options. The drug is also approved in Switzerland for the RA indication.